Ustekinumab is associated with superior effectiveness outcomes compared to vedolizumab in Crohn’s disease patients with prior failure to anti‐TNF treatment

BACKGROUND: Both vedolizumab and ustekinumab can be considered for the treatment of Crohn’s disease (CD) when anti‐TNF treatment fails. However, head‐to‐head trials are currently not available or planned. AIM: To compare vedolizumab and ustekinumab in Crohn´s disease patients in a prospective regist...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Aliment Pharmacol Ther
Asıl Yazarlar: Biemans, Vince B. C., van der Woude, C. Janneke, Dijkstra, Gerard, van der Meulen‐de Jong, Andrea E., Löwenberg, Mark, de Boer, Nanne K., Oldenburg, Bas, Srivastava, Nidhi, Jansen, Jeroen M., Bodelier, Alexander G. L., West, Rachel L., de Vries, Annemarie C., Haans, Jeoffrey J. L., de Jong, Dirk, Hoentjen, Frank, Pierik, Marieke J.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: John Wiley and Sons Inc. 2020
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7318204/
https://ncbi.nlm.nih.gov/pubmed/32441396
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/apt.15745
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller